Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Alzheimer's Amyloid: Structure, Function, and Disease
share announcement

Alzheimer's Amyloid: Structure, Function, and Disease

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Biochemistry, Biophysics and Computational Biology".

Deadline for manuscript submissions: closed (30 August 2023) | Viewed by 7263

Special Issue Editors

Dr. Adam Jarmuła

E-Mail Website
Guest Editor
Nencki Institute of Experimental Biology of the Polish Academy of Sciences, Warsaw, Poland
Interests: structural biology; computational biology; protein crystallography; molecular modeling; molecular docking; drug design; molecular dynamics
Special Issues, Collections and Topics in MDPI journals
Dr. Dariusz Stępkowski

E-Mail Website
Guest Editor
Nencki Institute of Experimental Biology of the Polish Academy of Sciences, Warsaw, Poland
Interests: Alzheimer’s disease; prion diseases; amyloidogenesis; inhibitors of amyloidogenesis; amyloid fibrils

Special Issue Information

Dear Colleagues,

Alzheimer’s disease (AD), a fatal neurodegenerative disease, has puzzled the scientific community for over a century. AD currently affects 50 million patients and is estimated to reach 152 million in 2050. The COVID-19 pandemic may have significantly increased these estimates according to an alarming report showing a hazard ratio of 1.69 for new-onset AD in older people as a late sequel of COVID-19.  This may substantially increase the already enormous burden on public health budgets, health care and older people and societies. Therefore, despite the controversial approval of an expensive therapy with aducanumab and expected approval of the use of monoclonal antibodies against β-amyloid, there is an urgent need to find cheap and effective small-molecule treatments for this disease. For this Special Issue, we welcome studies concerning inhibitors of β-amyloid aggregation into oligomers and mature fibrils as well as compounds dissolving mature fibrils. Computational studies docking new compounds to β-amyloid monomers, oligomers and fibrils and molecular dynamics experiments alone or preliminary to “wet” biochemistry leading to elucidation of the mechanism underlying the inhibition of aggregation or dissolution of fibrils are also encouraged.

Dr. Adam Jarmuła
Dr. Dariusz Stępkowski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • beta-amyloid
  • in silico studies
  • amyloidogenesis
  • inhibition of fibrillation
  • dissolution of amyloid fibrils

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 5764 KiB  
Article
Virtual Screening of a Marine Natural Product Database for In Silico Identification of a Potential Acetylcholinesterase Inhibitor
by Anushree Chandrashekhar Gade, Manikanta Murahari, Parasuraman Pavadai and Maushmi Shailesh Kumar
Life 2023, 13(6), 1298; https://doi.org/10.3390/life13061298 - 31 May 2023
Cited by 8 | Viewed by 2892
Abstract
Alzheimer’s disease is characterized by amyloid-beta aggregation and neurofibrillary tangles. Acetylcholinesterase (AChE) hydrolyses acetylcholine and induces amyloid-beta aggregation. Acetylcholinesterase inhibitors (AChEI) inhibit this aggregation by binding to AChE, making it a potential target for the treatment of AD. In this study, we have [...] Read more.
Alzheimer’s disease is characterized by amyloid-beta aggregation and neurofibrillary tangles. Acetylcholinesterase (AChE) hydrolyses acetylcholine and induces amyloid-beta aggregation. Acetylcholinesterase inhibitors (AChEI) inhibit this aggregation by binding to AChE, making it a potential target for the treatment of AD. In this study, we have focused on the identification of potent and safe AChEI from the Comprehensive Marine Natural Product Database (CMNPD) using computational tools. For the screening of CMNPD, a structure-based pharmacophore model was generated using a structure of AChE complexed with the co-crystallized ligand galantamine (PDB ID: 4EY6). The 330 molecules that passed through the pharmacophore filter were retrieved, their drug-likeness was determined, and they were then subjected to molecular docking studies. The top ten molecules were selected depending upon their docking score and were submitted for toxicity profiling. Based on these studies, molecule 64 (CMNPD8714) was found to be the safest and was subjected to molecular dynamics simulations and density functional theory calculations. This molecule showed stable hydrogen bonding and stacked interactions with TYR341, mediated through a water bridge. In silico results can be correlated with in vitro studies for checking its activity and safety in the future. Full article
(This article belongs to the Special Issue Alzheimer's Amyloid: Structure, Function, and Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 7506 KiB  
Review
Realization of Amyloid-like Aggregation as a Common Cause for Pathogenesis in Diseases
by Soumick Naskar and Nidhi Gour
Life 2023, 13(7), 1523; https://doi.org/10.3390/life13071523 - 7 Jul 2023
Cited by 6 | Viewed by 3505
Abstract
Amyloids were conventionally referred to as extracellular and intracellular accumulation of Aβ42 peptide, which causes the formation of plaques and neurofibrillary tangles inside the brain leading to the pathogenesis in Alzheimer’s disease. Subsequently, amyloid-like deposition was found in the etiology of prion diseases, [...] Read more.
Amyloids were conventionally referred to as extracellular and intracellular accumulation of Aβ42 peptide, which causes the formation of plaques and neurofibrillary tangles inside the brain leading to the pathogenesis in Alzheimer’s disease. Subsequently, amyloid-like deposition was found in the etiology of prion diseases, Parkinson’s disease, type II diabetes, and cancer, which was attributed to the aggregation of prion protein, α-Synuclein, islet amyloid polypeptide protein, and p53 protein, respectively. Hence, traditionally amyloids were considered aggregates formed exclusively by proteins or peptides. However, since the last decade, it has been discovered that other metabolites, like single amino acids, nucleobases, lipids, glucose derivatives, etc., have a propensity to form amyloid-like toxic assemblies. Several studies suggest direct implications of these metabolite assemblies in the patho-physiology of various inborn errors of metabolisms like phenylketonuria, tyrosinemia, cystinuria, and Gaucher’s disease, to name a few. In this review, we present a comprehensive literature overview that suggests amyloid-like structure formation as a common phenomenon for disease progression and pathogenesis in multiple syndromes. The review is devoted to providing readers with a broad knowledge of the structure, mode of formation, propagation, and transmission of different extracellular amyloids and their implications in the pathogenesis of diseases. We strongly believe a review on this topic is urgently required to create awareness about the understanding of the fundamental molecular mechanism behind the origin of diseases from an amyloid perspective and possibly look for a common therapeutic strategy for the treatment of these maladies by designing generic amyloid inhibitors. Full article
(This article belongs to the Special Issue Alzheimer's Amyloid: Structure, Function, and Disease)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop